Generic Name and Formulations:
Linagliptin 5mg; tabs.
Boehringer Ingelheim and Lilly
Indications for TRADJENTA:
Adjunct to diet and exercise in type 2 diabetes mellitus, as monotherapy or combination therapy. Limitations of use: not for treatment of type 1 diabetes or diabetic ketoacidosis. Not studied in patients with a history of pancreatitis.
5mg once daily.
<18yrs: not established.
Dipeptidyl peptidase-4 (DPP-4) inhibitor.
Monitor for signs/symptoms of pancreatitis; discontinue if suspected. History of angioedema to other DPP-4 inhibitors. Discontinue if a serious hypersensitivity reaction is suspected. Pregnancy (Cat.B). Nursing mothers.
Antagonized by strong P-gp or CYP3A4 inducers (eg, rifampin); consider alternatives to linagliptin if used in combination. May need lower dose of concomitant sulfonylurea or insulin to reduce risk of hypoglycemia.
Nasopharyngitis, hypoglycemia, arthralgia, back pain, headache; hypersensitivity reactions (eg, anaphylaxis, urticaria, angioedema, exfoliative skin conditions, bronchial hyperreactivity), myalgia, pancreatitis.
Enterohepatic (80%), renal (5%).
- 5mg tablets (Qty:30)
- appx. price $346.00
- Recall of Two IV Antibiotics Announced
- Peanut Allergy Patch Shows Promise in Latest Study
- Five Things ID Experts Want You to Know Before You Prescribe an Antibiotic
- What's Changed in Immunization Recommendations From CDC Advisory Committee
- IUD Approval Gives Women New Long-Acting Birth Control Option
- Limit Daily Use of Headphones, Warns WHO
- Sleep Deprivation Could Derail Healthy Eating Habits
- Not Enough COPD Patients Receiving Maintenance Tx, Research Suggests
- Harvoni for HCV Genotype 4, HIV Co-Infection Assessed in New Research
- Combo Therapy for HCV, HIV Co-Infection: New Data on Sustained Virologic Response